These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 17436025)

  • 21. The Efficacy of Palonosetron Plus Dexamethasone in Preventing Chemoradiotherapy-induced Nausea and Emesis in Patients Receiving Daily Low-dose Cisplatin-based Concurrent Chemoradiotherapy for Uterine Cervical Cancer: A Phase II Study.
    Mitsuhashi A; Usui H; Nishikimi K; Yamamoto N; Hanawa S; Tate S; Watanabe-Nemoto M; Uno T; Shozu M
    Am J Clin Oncol; 2017 Apr; 40(2):118-121. PubMed ID: 25144265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Palonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial.
    Celio L; Denaro A; Agustoni F; Bajetta E
    J Support Oncol; 2012; 10(2):65-71. PubMed ID: 22005217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.
    Celio L; Agustoni F; Testa I; Dotti K; de Braud F
    Tumori; 2012; 98(3):279-86. PubMed ID: 22825501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
    Grote T; Hajdenberg J; Cartmell A; Ferguson S; Ginkel A; Charu V
    J Support Oncol; 2006 Sep; 4(8):403-8. PubMed ID: 17004515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial.
    Boccia R; Grunberg S; Franco-Gonzales E; Rubenstein E; Voisin D
    Support Care Cancer; 2013 May; 21(5):1453-60. PubMed ID: 23354552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II trial of prophylactic olanzapine combined with palonosetron and dexamethasone for preventing nausea and vomiting induced by cisplatin.
    Maeda A; Ura T; Asano C; Haegawa I; Nomura M; Komori A; Narita Y; Taniguchi H; Kadowaki S; Muro K; Horio Y; Yoshida T; Oze I; Kajita M; Mizutani A
    Asia Pac J Clin Oncol; 2016 Sep; 12(3):254-8. PubMed ID: 27030364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of triple therapy with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy for gynecological cancer: KCOG-G1003 phase II trial.
    Takeshima N; Matoda M; Abe M; Hirashima Y; Kai K; Nasu K; Takano M; Furuya K; Sato S; Itamochi H; Tsubamoto H; Hasegawa K; Terao K; Otsuki T; Kuritani K; Ito K
    Support Care Cancer; 2014 Nov; 22(11):2891-8. PubMed ID: 24825735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study.
    Kovács G; Wachtel AE; Basharova EV; Spinelli T; Nicolas P; Kabickova E
    Lancet Oncol; 2016 Mar; 17(3):332-344. PubMed ID: 26795844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy.
    Kosaka Y; Tanino H; Sengoku N; Minatani N; Kikuchi M; Nishimiya H; Waraya M; Katoh H; Enomoto T; Sato T; Kuranami M; Watanabe M
    Support Care Cancer; 2016 Mar; 24(3):1405-11. PubMed ID: 26349772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single dose of palonosetron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy (HEC). Preliminary results.
    Lorusso V; Spedicato A; Petrucelli L; Saracino V; Giampaglia M; Perrone T
    Support Care Cancer; 2009 Dec; 17(12):1469-73. PubMed ID: 19294429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of the dexamethasone-sparing triplet regimen for preventing cisplatin-induced emesis: a combined analysis.
    Celio L; Bonizzoni E; Montani E; Aapro M
    Future Oncol; 2022 Sep; 18(30):3389-3397. PubMed ID: 36017782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy.
    Aogi K; Sakai H; Yoshizawa H; Masuda N; Katakami N; Yanagita Y; Inoue K; Kuranami M; Mizutani M; Masuda N
    Support Care Cancer; 2012 Jul; 20(7):1507-14. PubMed ID: 21808994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Usefulness of antiemetic therapy with aprepitant, palonosetron, and dexamethasone for lung cancer patients on cisplatin-based or carboplatin-based chemotherapy.
    Kitazaki T; Fukuda Y; Fukahori S; Oyanagi K; Soda H; Nakamura Y; Kohno S
    Support Care Cancer; 2015 Jan; 23(1):185-90. PubMed ID: 25063271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study.
    Rozzi A; Nardoni C; Corona M; Restuccia MR; Fabi A; Bria E; Minniti G; Lanzetta G
    Support Care Cancer; 2011 May; 19(5):697-701. PubMed ID: 20467757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase III Randomized Trial of Palonosetron and Dexamethasone With or Without Aprepitant to Prevent Nausea and Vomiting Induced by Full-dose Single-day Cisplatin-based Chemotherapy in Lung Cancer.
    Wu F; Lin X; Yang Z; Sun Z; Zeng F; Heng J; Qu J; Zeng L; Yang N; Zhang Y
    Clin Lung Cancer; 2018 Nov; 19(6):e913-e918. PubMed ID: 30197265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials.
    Celio L; Bonizzoni E; Bajetta E; Sebastiani S; Perrone T; Aapro MS
    Support Care Cancer; 2013 Feb; 21(2):565-73. PubMed ID: 22869054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New antiemetic drugs.
    Roila F; Fatigoni S
    Ann Oncol; 2006 Mar; 17 Suppl 2():ii96-100. PubMed ID: 16608997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Palonosetron in combination with 1-day versus 3-day dexamethasone to prevent nausea and vomiting in patients receiving paclitaxel and carboplatin.
    Furukawa N; Kanayama S; Tanase Y; Ito F
    Support Care Cancer; 2015 Nov; 23(11):3317-22. PubMed ID: 25947257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of palonosetron plus aprepitant in preventing chemoradiotherapy-induced nausea and emesis in patients receiving daily low-dose cisplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a phase II study.
    Hanawa S; Mitsuhashi A; Matsuoka A; Nishikimi K; Tate S; Usui H; Uno T; Shozu M
    Support Care Cancer; 2016 Nov; 24(11):4633-8. PubMed ID: 27286875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.